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Tuberculosis (TB) is an archaic disease caused by Mycobacterium tuberculosis (Mtb). The 
World Health Organization (WHO) established the “End TB Strategy” to reduce the incidence of 
TB. The Russian Federation is one of the seven high TB burden countries that have reached their 
2020 milestone goal to reduce TB incidence and deaths. Even though they are on target, they make 
up 8% of drug-resistant TB cases in 2019. Harmful and hazardous alcohol consumption is strongly 
associated with an increased risk of TB. When comparing the Russian Federation to other high TB 
burden countries, the prevalence of alcohol use disorder (AUD) is significantly higher. Through a 
literature review, the prevalence, treatment outcomes, and interventions of AUD among Russian 
TB patients are understood. The Russian Federation has a higher prevalence of alcohol abuse 
among TB patients and higher rates of TB mortality attributed to AUD. The integrated 
management of physician delivered alcohol care to TB patients (IMPACT) was a randomized 
control trial designed to identify how successful pharmacological and psychotherapy treatment is 
in TB patients with AUD. Unfortunately, the study did not find a significant improvement in 
treatment adherence. To overcome poor treatment outcomes in Russian TB patients with AUD, 
appropriate interventions should be identified and implemented in the Russian Federation. Such 
 v 
interventions would include encouraging Russians to seek treatment for AUD, decreasing 






Table of Contents 
Preface ............................................................................................................................................ x 
1.0 Introduction ............................................................................................................................. 1 
1.1 Pathogenesis .................................................................................................................... 2 
1.2 Prevention ....................................................................................................................... 5 
1.3 Screening and Diagnostics ............................................................................................. 5 
1.4 Treatment ........................................................................................................................ 7 
2.0 Global Tuberculosis .............................................................................................................. 11 
2.1 End Tuberculosis Strategy ........................................................................................... 12 
2.2 Determinants of Tuberculosis ..................................................................................... 12 
3.0 Alcohol Use Disorder ............................................................................................................ 15 
3.1 Side-Effects .................................................................................................................... 15 
3.2 Screening and Diagnostics ........................................................................................... 17 
3.3 Treatment ...................................................................................................................... 19 
3.4 Tuberculosis and Alcohol ............................................................................................. 20 
4.0 The Russian Federation ........................................................................................................ 21 
4.1 Tuberculosis .................................................................................................................. 22 
4.2 Alcohol ........................................................................................................................... 23 
4.2.1 Alcohol Policies .................................................................................................. 25 
4.2.2 Treatment for AUD ........................................................................................... 26 
5.0 Literature Review ................................................................................................................. 27 
5.1 Methods ......................................................................................................................... 27 
 vii 
5.2 Results ............................................................................................................................ 27 
5.2.1 Prevalence .......................................................................................................... 28 
5.2.2 Treatment Outcome .......................................................................................... 29 
5.2.3 Interventions ...................................................................................................... 29 
6.0 Discussion............................................................................................................................... 31 
7.0 Conclusion ............................................................................................................................. 33 
Appendix A Supplemental information for Alcohol Use Diagnosis (AUD) criteria and 
definitions................................................................................................................................. 34 
Appendix B Transtheoretical Table .......................................................................................... 36 
Bibliography ................................................................................................................................ 37 
 viii 
List of Tables 
Table 1 Example of AUDIT Questionnaire .............................................................................. 18 
Appendix Table 1 DSM-IV, DSM-5, ICD-10, and ICD-11 Alcohol Diagnosis Definitions .. 35 




List of Figures 
Figure 1 Tuberculosis Granuloma Model................................................................................... 3 
Figure 2 Incidence of Tuberculosis in 2019 .............................................................................. 11 
Figure 3 Prevalence of AUD ≥ 15 years in the top 30 High Burden Tuberculosis Countries
................................................................................................................................................... 21 
Figure 4 Correlation between alcohol sales and TB mortality by sex in the Russian 
Federation ................................................................................................................................ 22 
Figure 5 Prevalence of Heavy Episodic Drinking in ≥ 15 years in 2016 ................................ 24 
Figure 6 Recorded alcohol consumption in the Russian Federation from 1961 to 2016 ...... 24 




I want to thank Dr. Mattila and Dr. De Genna for helping me with the writing process and 
feedback on my essay. My friends and family were significant support mentally throughout the 
writing process and my program. I am thankful to the Department of Infectious Disease and 




Tuberculosis (TB) is a deadly infectious disease that has been affecting humans for 
thousands of years. Specialists found writings that describe a disease like TB in India and China, 
which dates back to 3300 and 2300 years ago, respectively [2]. Skeletal deformities associated 
with TB, Pott's disease, were found in Egyptian mummies dating back to 2400 BC and Peruvian 
mummies before European settlers arrived. Aristotle and Hippocrates started the debate on whether 
TB was an infectious agent or hereditary. This debate continued until Villeman proved the 
contagious nature of TB in 1865 through inoculation of rabbits with infected tissues from a cadaver 
[3]. Mycobacterium tuberculosis (Mtb), the bacillus that causes TB, was isolated and stained by 
Robert Koch and announced on March 24, 1882 [4]. After discovering Mtb, scientists began 
making great strides in identifying Mtb infections through scientific innovations such as the 
Tuberculin Skin Test (TST) and the Bacillus Calmette-Guerin (BCG) vaccine, which is widely 
used to prevent pediatric TB.  
Streptomycin was one of the first anti-TB drugs created to effectively treat patients with 
TB [3]. After a few years, Mtb became resistant to streptomycin and alternative anti-TB drugs. 
Drug-resistant TB challenges the World Health Organization’s (WHO) End TB Strategy [5]. 
Dubos commented over half a century ago that medical and social factors are essential to address 
TB patients [3]. Despite all the public health advances in TB prevention, diagnostic, and treatment, 
TB remains a substantial public health challenge requiring medical and social interventions to 




Mtb spreads from person to person through aerosol transmission. Interactions between the 
immune system and Mtb can follow several pathways that result in eliminating the bacteria or 
disease progression. First, the host immune response can successfully kill off Mtb [6, 7]. The 
second is where the host does not kill Mtb, and the bacilli can persist and cause active TB or 
asymptomatic latent TB (LTBI). Finally, LTBI can reactivate and lead to active TB equivalent to 
the disease seen after primary Mtb infection.   
The first immune cells that Mtb encounters are alveolar macrophages. They interact 
through cell surface receptors and phagocytose the Mtb [7, 8]. At some point, innate immune cells 
recognize the bacilli through recognition by toll-like receptors and produce cytokines and 
chemokines that activate and recruit other cells in the vicinity of the infection [7]. At some point, 
dendritic cells phagocytose Mtb and migrate to the lymph nodes to prime naïve T cells against 
Mtb. Immune cells at the site of infection produce pro-inflammatory and anti-inflammatory 
cytokines that help in the host's defense against Mtb [7, 9, 10]. A balance between pro-
inflammatory and anti-inflammatory cytokines is essential in granuloma formation. Excess 
inflammation damages surrounding tissues. If there are too many anti-inflammatory cytokines 
present, it can cause immunosuppression [9]. 
Mtb has evolved strategies to evade the host's immune response. After phagocytosis, Mtb 
prevents fusion of the phagosome, and lysosome will not occur, creating an intracellular niche for 
bacterial replication. Macrophage and monocyte apoptosis can decrease the viability of Mtb and 
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kill the bacilli. Mtb has the ability to manipulate immune cells and promote necrosis. This cell 
death pathway can promote bacterial dissemination without reducing the viability of Mtb. 
 
Figure 1 Tuberculosis Granuloma Model 
Source : Balcells et al., 2019 
 
 
The host's innate immune response facilitates the formation of a granuloma [10]. 
Granulomas are compact structures that consist of immune cells that coordinate to either kill the 
bacterium or, in cases where coordination is unsuccessful, promote bacterial persistence [11].  The 
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center of granulomas is a hypoxic environment that prevents Mtb from growing [12]. Cytokines 
important in granuloma formation include tumor necrosis factor, interferon-γ, and interleukin-12 
[10]. If cytokine expression is deficient, then the granulomas become unstable. This allows the 
Mtb to replicate and disseminate to surrounding cells. When the immune system is compromised 
by host aging, co-morbidities, or co-infections (especially HIV), immunity in granuloma can 
weaken, allowing Mtb access to the oxygen and nutrients the bacteria need for replication and 
eventual dissemination to surrounding cells and other tissues [12, 13].  
Consumption and phthisis are earlier names for TB that refer to the severe wasting of 
individuals with TB. The main symptoms of active pulmonary TB disease are fever, night sweats, 
weight loss, fatigue, and cough [5, 14]. These symptoms begin to set in slowly and make it difficult 
for patients to identify a problem. This results in a delay in the patient’s effort in seeking diagnosis 
or treatment until several weeks after the onset of symptoms. For individuals with extrapulmonary 
TB, the diagnosis can be elusive. Based on the tissues that Mtb infects, patients can experience 
different symptoms. The most common forms of extrapulmonary TB are lymphatic, meningitis, 
and skeletal. Patients with extrapulmonary TB have a 10-50% chance of having pulmonary TB 
[15]. A patient with lymphatic TB may have pulmonary TB symptoms, except they will not cough 
[16]. Meningitis TB causes inflammation to the meninges and causes symptoms like other bacterial 
meningitis infections. Patients with skeletal TB experience pain and inflammation at the site of 
infection while Mtb destroys the bone.  
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1.2 Prevention 
In 1921, Albert Calmette and Camille Guérin introduced the Mycobacterium bovis 
Calmette- Guérin  (BCG) vaccine [17], which is based on an attenuated strain of M. bovis. More 
than 14 strains of BCG are distributed throughout the world and offer variable levels of protection 
against TB [18]. The BCG vaccine is up to 80 % effective in preventing TB in some cases, but the 
duration of safety and overall protective effects are highly variable [19]. Considering this, the 
WHO recommends vaccination of infants with the BCG vaccine in high incidence countries [20]. 
Several countries provide revaccination in citizens after infancy, although the WHO recommends 
only one dose of the BCG vaccine [21]. Revaccination in adults is effective in reducing the 
incidence of pulmonary TB [20]. Due to the BCG vaccine's variable protection, several new TB 
vaccines are being developed. They are in various stages of testing, in some cases with promising 
results [20]. 
1.3 Screening and Diagnostics  
Early detection of TB is essential for controlling the spread of TB. The TST and Interferon-
gamma release assays (IGRAs) can identify an individual with Mtb exposure [22, 23]. TST is 
injected intradermally into an individual's arm with purified protein derivatives (PPD). If the 
person has a mycobacterial infection, TST will elicit type IV delayed hypersensitivity [22]. When 
an individual has a positive TST, a chest x-ray (CXR) can allow a physician to see if there are 
lesions in the lung. If there is no lesion present in the CXR, then the TST results are considered a 
false positive. TST has low sensitivity, and false positives are common among people who have 
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been vaccinated with BCG or are immunocompromised.  The TST’s sensitivity is further 
compromised if an individual is vaccinated with the BCG vaccine more than once [21]. IGRAs 
assess the release of IFN-γ in blood drawn from an individual. IGRAs overcome the TST's cross-
reactivity with BCG to reduce the number of false positives when screening TB. Due to the cost 
of IGRAs, TST is more favorable for use when screening for TB in high burden areas. 
When an individual is symptomatic, they complete a questionnaire and receive a CXR to 
screen them for the risk of active pulmonary TB. If the results are positive for active TB, then they 
are referred to a specialist. Sputum smear microscopy, mycobacterial culture, and nucleic acid 
amplification tests (NAATs) are tests used to identify the presence of Mtb. Low-income countries 
favor sputum smear microscopy since it the least expensive out of the three and does not require a 
biosafety level 3 (BSL3) laboratory [24, 25]. Cultures and NAATs both require a BSL3 laboratory 
to be conducted but have a higher sensitivity than smear microscopy. The WHO recommends 
using Xpert MTB/RIF, a NAAT method that can produce results in about 2 hours [26]. Other tests 
the WHO recommends are Xpert Ultra and Truenat assays. Diagnosing extrapulmonary TB is 
more challenging since Mtb must be cultured from the site of infection. Extra-pulmonary TB is a 
paucibacillary disease that affects the sensitivity of diagnostic tests [15]. Biopsies and body fluids 
are collected to identify the presence of Mtb. Xpert MTB/RIF is helpful for testing for 
extrapulmonary TB and can be tested in children [24, 26] 
Drug susceptibility testing (DST) is used to determine if a TB patient is resistant to anti-
TB drugs [24, 27]. There are three drug-resistant TB known as rifampicin-resistant TB (RR-TB), 
multidrug-resistant TB (MDR-TB), and extensively drug-resistant TB (XDR-TB) [27, 28]. RR-
TB is when the TB is resistant to rifampicin. A TB case is classified as MDR-TB when the strain 
is resistant to rifampicin and isoniazid [27, 29, 30]. XDR-TB is when the TB strain is resistant to 
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any of the fluoroquinolone drugs and at least one injectable second-line drug. Drug-resistant TB 
is acquired through chaotic drug treatment or direct transmission [27, 31].  
There are two main routes researchers can go with DST, phenotypic and genotypic testing 
using culture and NAATs methods [24]. Culture methods such a solid agar or liquid are used for 
phenotypic DST [24]. If Mtb can persist in the presence of certain anti-TB drugs, then Mtb is 
considered resistant to them. It may take weeks or up to a couple of months to receive the results 
from the culture-based methods. This is not effective for treating patients with potential MDR-TB 
or XDR-TB [29, 31]. Genotypic testing is more sensitive for detecting which drugs the patient is 
resistant to [24]. Xpert MTB/RIF and line probe assays (LPAs) are more effective at detecting 
rifampicin resistance and second-line drug resistance, respectively [24]. 
1.4 Treatment 
When an individual is diagnosed with active TB, they are enrolled in treatment to prevent 
the progression of the disease. The WHO classified all anti-TB drugs into six groups [27, 32]. The 
groups are classified according to efficacy and toxicity. Group 1 consists of all first-line drugs: 
isoniazid, rifampicin, pyrazinamide, and ethambutol. Rifampicin is the most effective anti-TB drug 
currently available for treatment. The other groups are all classified as second-line drugs. These 
drugs are more toxic than first-line drugs and are not effective at clearing Mtb [32]. Group 2 
consists of the fluoroquinolones: high dose levofloxacin, gatifloxacin, and moxifloxacin. Group 3 
consists of the newer drugs, including bedaquililine, delamanid, and linezolid. Group 4 is made up 
of injectable agents. The main injectable anti-TB drugs are amikacin, kanamycin, streptomycin, 
and capreomycin. Since group 4 anti-TB drugs are injectables, patients would have to travel to the 
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hospital for routine treatment. Group 5 consists of ethionamide/prothionamide, clofazimine, 
imipenem, and meropenem. The final group, Group 6, is made up of amoxicillin/clavulanate, 
cycloserine, and para-aminosalicylic acid, and clarithromycin. 
Screening for TB identifies primarily LTBI, which means Mtb is non-replicating, and the 
patient has no clinical manifestations of the disease [33]. A patient infected with LTBI has about 
a 10-15% chance of progressing to active TB throughout their life. When an individual is 
diagnosed with LTBI, they undergo treatment to sterilize the lung environment of Mtb bacilli. The 
WHO guidelines for treating patients with LTBI include a 6- or 9-month regimen of isoniazid, 3-
4 months of rifampicin, or 3-month weekly rifapentine plus isoniazid [34]. The 6- and 9-month 
isoniazid treatment plan is slightly more hepatoxic and longer than the other two treatment options; 
patients may not adhere to the regimen as well [34]. 
Newly diagnosed TB patients with drug-sensitive TB start on first-line anti-TB drugs.  
With newly diagnosed TB patients, a combination of all four is taken for the first two months of 
treatment. This is followed up by taking just isoniazid and rifampicin for the next 4-6 months [35]. 
The first two months of treatment are the intensive phase for TB treatment. The length of treatment 
for TB is long because Mtb is a slow-growing pathogen that occupies different granuloma 
microenvironments, which results in varying levels of drug penetrance across microenvironments. 
Consequently, it will take more time to sterilize the lung environment thoroughly. Oral medication 
is an effective method for administrating medications since patients do not have to travel to the 
hospital for treatment every day. Patients must have a sputum smear test done during their regimen 
to ensure they respond appropriately to the drugs [36]. Suppose the patient still has a positive 
sputum smear test at the end of their treatment regimen. In that case, they will receive a DST  to 
identify potentially specific drug resistance. Once the sputum smear test is negative, patients will 
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undergo another round of treatment with second-line medications if they fail their first round. 
Extra-pulmonary TB treatment regimen guidelines are the same as for pulmonary TB [15]. Patients 
with meningitis and skeletal TB receive treatment for 9-12 months.  
Based on the WHO's recommendations, patients with drug-resistant TB can undergo a 
short-course treatment if eligible for 9-12 months, but most treatment regimens are 18-24 months 
long [27, 30, 34]. The WHO established a drug classification in 2016 specified for drug-resistant 
TB patients [32, 37]. There are four anti-TB drug categories, A-D. In group A are the 
fluoroquinolones, group B are the injectable medications, and group C consists of other major 
second-line drugs. There are three subgroups in group D: D1, D2, and D3. All the D subgroups 
consist of anti-TB additional medications, but D1 has two first-line anti-TB drugs, pyrazinamide, 
and ethambutol. The grouping of these drugs is functional when doctors create a treatment regimen 
for a patient that has a drug-resistant strain.  Even though the classification was designed initially 
for RR-TB, doctors can use it for MDR- and XDR-TB. The WHO recommends that the patients 
are on four effective drugs against Mtb for the first six months and then at least three medications 
for the rest of the treatment course [36]. A patient with drug-resistant TB should have at least one 
drug from group A and group B in their drug cocktail. A DST is helpful for clinicians when 
determining which drugs would best treat a patient with drug-resistant TB. 
The length of the treatment regimen and toxicity of anti-TB drugs make it difficult to treat 
patients without interruptions. Interruptions may involve a patient having to stop treatment due to 
side effects or failure to adhere to a treatment regimen. The reduction in adherence can be due to 
patients believing that they are cured, thus discontinuing their treatment, or patients may decide to 
stop taking their medications. Side-effects from anti-TB drugs include hepatoxicity, 
gastrointestinal distress, nephrotoxicity, hypothyroidism, neurotoxicity, and ototoxicity [27, 34]. 
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About 15% of patients with drug-susceptible TB experience side-effects that cause them to 
discontinue their treatment [38]. About 86% of MDR-TB patients experience adverse side effects 
from anti-TB drugs [39]. Patients should be monitored for side effects during treatment to ensure 
treatment is stopped immediately when symptoms of toxicity become apparent.  
The cure rate for MDR-TB is 60-80%, and XDR-TB's cure rates are even lower [31, 40]. 
These cure rates are only that high when socioeconomic interventions are incorporated into 
treatment. One of the main concerns that healthcare providers face with MDR- and XDR-TB 
patients is ethical treatment. Patients with drug-resistant TB can transmit their drug-resistant 
bacteria to other people. If a patient fails to complete treatment for XDR-TB, the median timeframe 
for death is 19.8 months [31]. Due to the risk of ongoing transmission, these TB patients are closely 





Figure 2 Incidence of Tuberculosis in 2019 
WHO, 2020 
In 2019, there were around 10 million new cases and about 1.4 million deaths from TB. Of 
these 10 million cases, about 90% of them were in adults [5]. According to the WHO, TB was one 
of the top 10 leading causes of death worldwide in 2019. Of the approximate 10 million TB cases, 
about 465,000 were MDR-TB. Globally, MDR/RR-TB makes up 3.3% of all TB cases in 2019. 
About 18% of MDR/RR-TB were previously treated for TB cases. The regions with the highest 
burden of MDR-TB and XDR-TB are China, India, and the Russian Federation [5, 41]. TB is 
treatable, but individuals diagnosed with MDR-TB have a mortality of 40%, while XDR-TB is 
60% [5].  
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2.1 End Tuberculosis Strategy 
In 2015, the WHO established the 'End TB Strategy' initiative to end the global TB 
epidemic. An indicator the WHO is using is a 95% reduction of global TB burden and deaths by 
2035 compared to 2015 [5]. TB must be efficiently diagnosed, treated, and discussed with patients 
for prevention purposes to accomplish this goal.  The WHO began implementing a new TB control 
strategy called “Directly Observed Treatment, short-course (DOTS)” in the early 1990s. DOTS 
focuses on five elements: sustained political and financial commitment, diagnosis of TB through 
practical sputum smear microscopy, a standardized short-course monitored TB treatment, ample 
supply of anti-TB drugs, and a standardized method for recording and reporting TB cases [29]. 
This strategy revolves around treating infectious TB patients with a shorter treatment regimen. In 
the year 2000, WHO implemented DOTS-plus was built off DOTS concepts, with the addition of 
quality second-line anti-TB drugs provisions [29].  
 
2.2 Determinants of Tuberculosis 
Determinants of TB can increase an individual's risk of exposure, treatment-seeking, 
reactivation of Mtb, adherence, and relapse. Identifying high-risk populations will allow for the 
development of a targeted intervention. The main determinants of TB involve host characteristics, 
health system socioeconomic status, and behavioral risk factors associated with TB.  These 
determinants can be split into endogenous and exogenous factors. 
 13 
Host characteristics are endogenous factors that influence the progression of TB [42]. Adult 
men make up 56% of TB cases confirmed in 2019. In comparison, adult women make up 32%, 
and children make up 12% of TB cases in 2019 [5]. Co-morbidities such as diabetes mellitus 
increase a host’s risk of progressing to active TB. In 2019, diabetes mellitus increased an 
individual’s risk of TB by 1.5 fold and attributed to 0.35 million cases of TB, 3.1%, in 2019 [5]. 
About 0.76 million TB cases were associated with the human immunodeficiency virus 
(HIV) in 2019, which correlates to 7.7% of TB infections attributed to HIV co-infection [5]. HIV 
is an infectious agent that attacks the immune system. About 38 million people are living with HIV 
as of 2019 [43]. HIV left untreated can progress to acquired immunodeficiency syndrome (AIDS), 
which is the most advanced stage of HIV infection. HIV is spread through bodily fluids such as 
blood, semen, vaginal fluids, and breast milk [43]. Sharing needles and unprotected sex are risk 
factors for HIV. A patient with HIV must start on antiretroviral treatment (ART), which inhibits 
the replication of HIV, immediately after diagnosis [44]. By inhibiting HIV replication, the patient 
can live longer and healthier while decreasing the risk of transmission to others [44]. If HIV is left 
untreated, then the patient is vulnerable to potentially fatal infections such as TB. TB is one of the 
leading causes of death in HIV individuals since 1 in 3 HIV-infected patients die from TB [43]. 
 About 71% of TB patients receive full coverage for their treatment worldwide [5]. Treating 
patients for drug-susceptible TB costs about $860/person [5]. The cost increases to about $5,659/ 
person if the patient has MDR-TB [5]. TB patients face catastrophic costs due to paying out of 
pocket for TB treatment, transportation to TB clinics, missing work, and job loss [5]. Countries 
without universal healthcare coverage for TB patients are likely to see patients defaulting since 
they cannot afford treatment [42].  
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Socioeconomic status and living conditions impact an individual's exposure to Mtb, the 
progression of TB, and adherence. In 2019, 2.2 million cases of TB were attributed to 
undernourishment[5]. This is a significant point to consider because poverty is commonly 
associated with an increased risk of TB. Undernourished individuals are 3.2 times more likely to 
develop active TB. Those who progress to active disease that lack education on TB are less likely 
to self-diagnose themselves or adhere to their treatment regimen. Unemployment and 
homelessness are associated with an increased risk for exposure and progression of Mtb infection. 
Indoor air pollution from wood-burning stoves impairs an individual's immune system. It increases 
their risk of susceptibility to illness and progression of the disease [42]. Overcrowding has a strong 
association with an increased risk of exposure to Mtb [42]. Examples of overcrowding are prisons 
and social gatherings.  
Behavioral risks include alcohol consumption and smoking. Both are unhealthy behaviors 
that can lead to an addictive disorder and an increased risk of TB. With 2.35 billion people 
consuming alcohol each year and 1.3 billion using tobacco, both raise a significant public health 
concern [45]. Alcohol consumption and smoking can lead to health side-effects such as liver 
cirrhosis and chronic obstructive pulmonary disease (COPD), respectively. It was estimated that 
0.72 million TB cases were related to Alcohol Use Disorder (AUD), and 0.70 million cases were 
related to smoking [5]. Individuals are 3.3 and 1.6 times more likely to develop TB if they have 
AUD or smoke, respectively [5]. Individuals can be at a higher risk for adverse effects, poor 




3.0 Alcohol Use Disorder 
Alcohol is a psychoactive substance that can be considered toxic and deadly when abused 
[46]. Alcohol consumption contributes to premature deaths worldwide and is one of the leading 
behavioral causes of death [47]. Wine, beer, and spirits are different forms of alcohol. Beer 
typically contains about 5% alcohol, wine has 12% alcohol, and spirits are 40% alcohol [48]. A 
standard drink equates to 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of spirits. The National 
Institute on Alcohol Abuse and Alcoholism (NIAA) recommends males to consume no more than 
14 drinks and females to consume no more than seven drinks a week [49]. The standard drink 
contains 14 grams of pure alcohol. The WHO estimated that 2.35 billion people, 15 years and 
older, consumed alcohol over the past 12 months in 2016. About 3 million deaths per year are 
related to alcohol consumption [45]. In 2016, about 8.6% of men and 1.7% of women had an AUD 
[45]. A person with AUD does not have the ability to stop or control their alcohol consumption 
even if it may negatively impact their health and others around them [45]. 
3.1 Side-Effects 
Over 200 diseases and injuries worldwide are related to harmful and hazardous alcohol 
consumption [50]. Based on the amount of alcohol consumed and drinking patterns, chronic or 
acute outcomes may occur [51]. Heavy alcohol consumption in males is considered to be four or 
more drinks. For females, three or more drinks in two hours are classified as binge drinking. Binge 
drinking is when the blood alcohol content (BAC) of 0.08% in two hours [45]. To achieve a BAC 
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of 0.08% in two hours, men must consume four or more drinks, and a female must consume three 
or more drinks. Alcohol overdose occurs when BAC is around 0.35% [45]. Heavy alcohol 
consumption can negatively impact a person biologically, socioeconomically, and others around 
them [50]. 
Alcohol consumption affects an individual’s health by impairing the immune system, organ 
damage, and nutritional deficiency [47, 52, 53]. Chronic alcohol consumption is associated with 
an increase in pro-inflammatory cytokines, which downstream promotes inflammation in the 
lungs, bowels, brain, pancreas, and liver [54]. Acute alcohol exposure increases IL-10 cytokine, 
but chronic alcohol exposure inhibits anti-inflammatory cytokine production to counteract 
inflammation [54]. Alcohol consumption is often associated with cirrhosis of the liver and 
gastrointestinal distress due to inflammation [47, 54]. Inflammation of the gastrointestinal inhibits 
the body’s ability to absorb necessary nutrients and results in nutritional deficiencies.  
Those suffering from AUD are more likely to experience social exclusion, stigmas, and 
psychiatric problems [51]. AUD is associated with job loss, homelessness, and loss of social 
network [52, 53]. Heavy alcohol consumption is related to increased incarceration rates and 
stigmatization [52]. Psychiatric problems that can arise from heavy alcohol consumption are 
depression, anxiety disorders, personality disorders, mania, and suicide [47]. Individuals with 
AUD that live in poverty are at risk for exposure to infectious agents due to poor hygiene and 
overcrowding [52]. 
Individuals that consume frequent and voluminous quantities of alcohol have decreased 
cerebral blood flow, which affects memory and disrupts their ability to abstain from alcohol short-
term. They may also experience impairment of cognitive function, inhibiting their ability to 
process speech and emotional signals. Once a person reaches a BAC of 0.05%, their driving is 
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impaired [45]. Aggressive behavior occurs when their BAC is about 0.075%. Driving impairment 
and aggressive behavior can lead to road injuries and violence that affect the person and others. 
Alcohol consumption is associated with risky sexual behaviors such as unprotected sex, partner 
selection, and sexual violence [45]. These behaviors can increase the likelihood of a person 
contracting HIV, which increases their chances of contracting TB. 
3.2 Screening and Diagnostics 
The Alcohol Use Disorder Identification Test (AUDIT) is a test that allows healthcare 
providers to screen individuals for harmful alcohol use [55]. AUDIT questions can be broken into 
three primary measurements: consumption, dependence, and consequences [55]. The test has ten 
questions where each answer has a score from zero to four. Table 1 is an example of the AUDIT 
questionnaire with a unit guide on top.  The user adds up the scores on all ten questions to 
determine if they have concerning alcohol use. A total score of eight or greater indicates harmful 
and hazardous alcohol use [56]. When an individual receives a score of eight or higher, they are 
referred to a specialist for diagnostic testing. 
The Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International 
Classification of Diseases (ICD) both define human disorders and what criteria must be met to 
diagnosis a patient with that disorder [51, 57]. The DSM is published by the American Psychiatric 
Association, and the WHO publishes the ICD. In the DSM-IV, alcohol dependence and alcohol 
abuse were two separate diagnoses. ICD-10 uses alcohol dependence syndrome as the primary 
alcohol diagnosis based on the definition of alcohol diagnosis in the DSM-IV [57]. The ICD-11, 
released in 2019, still uses alcohol dependence as its main classification for alcohol disorders but 
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included hazardous use of alcohol as another classification [57]. The DSM-5, released in 2013, 
encompasses the alcohol diagnosis from ICD-10, ICD-11, and DSM-IV into one category: AUD 
[57]. The definition of AUD is “a problematic pattern of alcohol use leading to clinically 
significant impairment or distress, as manifested by at least 2 of the criteria occurring within 12 
months” [57]. There 11 criteria used to diagnose AUD are listed in Appendix Figure 1.  
Table 1 Example of AUDIT Questionnaire 




When an individual starts rehabilitation for AUD, they meet with a specialist to make a 
treatment plan. Therapy talk and medication-assisted treatment are the two main treatment courses 
[58]. An individual can receive treatment as an outpatient, inpatient, partial hospitalization, or in 
their residence. Once individual sets up their treatment plan with a specialist, they may undergo 
detox. In this stage, the individual completely stops consuming alcohol. Patients with AUD that 
go through detoxification may go through medical distress and require the supervision of a 
specialist. A patient can begin experiencing withdrawal symptoms as early as 6-12 hours after their 
last drink [59]. Symptoms range across somatic, emotional, and psychotic [59, 60]. The WHO 
recommends using benzodiazepines, antipsychotic, and psychoactive medications to treat patients 
experiencing alcohol withdrawal symptoms [61]. For continued recovery, pharmacological 
interventions such as acamprosate, disulfiram, naltrexone, or baclofen can prevent alcohol 
cravings and promote abstinence [59, 62]. About 5 % of patients experience delirium tremens 
when going through detox [59]. Delirium tremens is a severe symptom of withdrawal that occurs 
about five days after the onset of withdrawal symptoms. Patients will present as disoriented and 
have disturbances with memory, attention, language, and visuospatial ability that fluctuate 
throughout the day. These symptoms are often missed since very few patients exhibit them [60]. 
Psychosocial interventions for continued recovery include behavioral therapies, twelve-step 
facilitation, social network, contingency management, psychodynamic therapy, and cognitive-
behavioral couple therapy [59, 63] 
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3.4 Tuberculosis and Alcohol 
Alcohol and TB are causally linked, and they are both “diseases of poverty” [52, 64]. The 
diagnosis of AUD increases an individual’s risk of having TB by threefold [65]. AUD is 
significantly associated with MDR-TB [66]. In addition, AUD increases the risk of susceptibility 
and progression of TB through social behaviors, immunosuppression, and treatment adherence. 
Social behaviors such as frequenting pubs, bars, and other social drinking venues place 
individuals at a higher risk for exposure to TB since they congregate settings. Individuals with 
AUD may frequent those venues more than others. Once an individual is infected with Mtb, they 
are about three times more likely to progress to active TB than those who do not consume excessive 
amounts of alcohol or have AUD. Patients with concomitant TB and AUD experience social 
problems that delay their diagnosis and treatment [52, 53]. These problems include homelessness, 
lack of a social network, and inadequate health literacy to self-diagnosis themselves with TB. 
Heavy alcohol consumption can impair a person’s immune system. Acute and chronic 
alcohol consumption may lead to poor self-regulation of inflammation and inhibition of alveolar 
macrophages [52]. Through dysregulation of the immune response, the host is susceptible to 
microbial infections. This increases the risk of progressing to active TB. Studies have shown that 
alcohol interacts poorly with anti-TB drugs and interferes with metabolism and absorption [52]. 
Alcohol is also significantly associated with poor treatment adherence among TB patients 
[66]. Poor outcomes include a positive-sputum smear test at the end of treatment and require 
retreatment, interruptions due to adverse side effects, and failure to complete treatment (default) 
[46]. Individuals suffering from AUD are at a greater risk for relapse and developing MDR-TB 
[67]. Alcohol consumption during treatment increases the difficulty of managing MDR-TB.  
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4.0 The Russian Federation 
Comparing the Russian Federation with other high TB burden countries, the Russian 
Federation has a similar prevalence of diabetes mellitus and smoking but a lower prevalence of 
undernourishment than other high TB burden countries [5]. The Russian Federation has a 
significantly higher prevalence of AUD compared to other high TB burden countries. In the 
Russian Federation, about 7.4% of females and 37% of males were diagnosed with AUD (Figure 
3). The average prevalence of AUD in the high burden TB countries, excluding the Russian 
Federation, is 1.1% in females and 7.3% in males. Figure 4 shows a correlation between alcohol 
sales and TB mortality in the Russian Federation, requiring further investigation. Due to the high 
prevalence of AUD in the Russian Federation, especially among males, it would be imperative to 
understand TB and AUD in the country and the potential interaction between both conditions. 
 
Figure 3 Prevalence of AUD ≥ 15 years in the top 30 High Burden Tuberculosis Countries 






































































































































































































Figure 4 Correlation between alcohol sales and TB mortality by sex in the Russian Federation 
Source: Razodovsky, 2014 
4.1 Tuberculosis 
The Russian Federation is one of the top 30 high burden TB countries [5]. Throughout the 
20th century, the Russian Federation revised its TB intervention and steadily decreased in cases 
until 1990 [68]. After the Union of Soviet Social Republics (USSR) collapsed in Dec. 1991, the 
Russian Federation scaled back on TB screening and anti-TB drug distribution [68]. Throughout 
the 1990s, the Russian Federation saw a spike in TB cases. It quickly became one of the highest-
burden TB countries. In 2000, the Russian Federation hit its peak TB incidence of about 90 per 
100,000. The WHO tried to get the Russian Federation to adopt DOTS in the 1990s but failed [68]. 
After the WHO revised DOTS in 1999, the Russian Federation began to adopt the system into their 
TB program in 2000 and now incorporate DOTS-plus for MDR-TB patients [68]. 
In 2019 the Russian Federation reported a TB incidence of 50 per 100,000 [69]. According 
to the WHO 2020 TB Report, the Russian Federation reached its 2020 milestone for TB incidence 
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reduction and mortality. The Russian Federation reduced TB incidence by 19% and TB mortality 
by 35% between 2015 to 2019 [5]. Although the Russian Federation is declining in TB cases, it is 
still one of the top 30 high TB burden countries in 2019. Even though the Russian Federation has 
seen a significant drop in TB incidence, they had a 6% increase in MDR-TB cases from 2010-
2019 [5]. The Russian Federation is one of the top three countries for MDR-TB and makes up 8% 
of the world’s MDR-TB cases [5].  
The demographic of TB cases in the Russian Federation is 68% male. Russian males ages 
35-44 are the highest impact in the Russian Federation [69]. The incidence of HIV-positive TB 
cases is 12 per 100,000 in the Russian Federation, which is higher than the global incidence of 
HIV-positive TB cases. The rate of MDR/RR-TB cases is 27 per 100,000 in the Russian 
Federation, which is more than half of their total TB incidence in 2019. About 71% of MDR/RR-
TB cases have been previously treated for TB. The high TB mortality in the Russian Federation is 
attributed to MDR-TB and XDR-TB. Non-adherence during TB treatment is associated with drug 
resistance in the Russian Federation [70]. 
4.2 Alcohol  
The ‘drinking culture’ in the Russian Federation is a social custom [71]. The Russian 
Federation has one of the highest rates of hazardous drinking globally, highlighted in Figure 5 
[45]. As seen in Figure 6, the Russian Federation's peak alcohol consumption was in the early 
2000s but has declined to under 10 liters per capita in 2019 [72]. After the collapse of the Soviet 
Union, the population health in the Russian Federation declined. From 1991 to 1994, the life 
expectancy in the Russian Federation dropped from 63.4 to 57.4 years in males and 74.2 to 71.1 
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years in females [73]. The decline in life expectancy is due to a breakdown in the healthcare 
system. Citizens are experiencing psychological stress from economic and political distress [73]. 
The fluctuation in life expectancy in the Russian Federation is also firmly attributed to alcohol 
[74]. From 1991 to 2000, there were about 400,000 to 700,000 premature deaths per year from 
alcohol consumption [75]. 
 
Figure 5 Prevalence of Heavy Episodic Drinking in ≥ 15 years in 2016 
Source: WHO, 2018 
 
Figure 6 Recorded alcohol consumption in the Russian Federation from 1961 to 2016 
Source: WHO, 2018 
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4.2.1  Alcohol Policies 
The Russian Federation recognized that alcohol consumption is a significant health concern 
in the early 2000s. From 1985-88, Gorbachev's anti-alcohol campaign successfully reduced 
alcohol consumption, as seen in Figure 6. During the anti-alcohol campaign, deaths related to 
alcohol dropped from 23 per 100,000 to 9.1 per 100,000 [71]. Not long after Gorbachev's campaign 
ended, the Soviet Union collapsed while alcohol consumption skyrocketed [76]. The Russian 
Federation implemented new policies regarding alcohol distribution and production throughout 
the 2000s to decrease alcohol consumption and stop the production of homemade alcohol [77].  
 In 2005 and 2006, prices for vodka increased to discourage citizens from buying vodka. It 
was observed that violent crimes, premature death, and incarceration rates were positively 
associated with the consumption of spirits [72, 78]. As seen in  Figure 3, the Russian Federation 
successfully decreased the consumption of spirits [75, 79]. The Russian Federation established the 
Federal Service for Alcohol Market Regulation to reduce alcohol disorders and promote a healthy 
lifestyle starting in 2010 [72]. The Russian Federation also established 14 tasks to achieve by 2020. 
One of these tasks included establishing the Unified State Automated Information System 
(EGAIS) in 2016. EGAIS is an advanced monitoring system for alcohol production and sales [72]. 
In 2018, the Russian Federation established AUDIT as a standardized screening tool for hazardous 
and harmful alcohol use [72]. From 2007 to 2018, the Russian Federation has seen a 39.6% 
decreases in alcohol consumption [80]. This decrease was seen across light to heavy drinkers. 
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4.2.2  Treatment for AUD 
The Russian Federation has a narcology treatment clinic where patients can receive 
registered treatment for AUD. Patients can receive unregistered treatment if they pay out-of-pocket 
through private healthcare providers [72]. The Russian Federation has substance abuse specialists 
called narcologists responsible for dealing with prevention treatment, diagnosis, AUD, and social 
care and recovery of drug-dependent patients. They are the primary providers that help patients 
undergo detox and treatment. While patients go through detox and pharmacological interventions, 
they are monitored by a psychologist to assess their mental state and provide counseling and 
psychotherapy throughout their treatment [55]. Russians fear the stigmatizing narcology registry 
because they can potentially lose their driver’s license or job [81]. There were no standardized 
screening tools for AUD in the Russian Federation until 2015 [72].  
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5.0 Literature Review 
The objective of the literature review is to identify the relationship between AUD and TB 
among patients living within the Russian Federation. Articles should identify the prevalence of 
AUD among TB patients, their risk for poor treatment outcomes, and measurements of alcohol 
consumption. Targeted interventions should be created and implemented to address potential 
increases in AUD cases, an individual’s risk for TB, progression to drug-resistant TB, as well as 
ineffective treatment outcomes. 
5.1 Methods 
A search was conducted on Pubmed to identify articles that used ‘Tuberculosis,’ ‘Alcohol,’ 
and ‘Russia.’ Full-text articles that included studies related to AUD, alcohol abuse, dependence, 
and addiction was also included. These articles were analyzed and identified based on three 
criteria: the type of study design, data collection methods, and analysis. Articles in a different 
language, solemnly review articles, or articles that lacked a central focus on the Russian Federation 
were excluded from this analysis. 
5.2 Results 
A total of 105 articles were found on Pubmed. After excluding articles that did not match 
the criteria, 21 articles were used for the literature review. The primary study designs were focus 
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group, retrospective cohort study,  prospective cohort study, and randomized control trial. The 
articles identified data collection through previous medical documentation of alcohol abuse or 
alcohol dependence by a trained clinician or narcologist or questioned participants. Only five 
articles used AUDIT for measuring hazardous alcohol use [55, 82-85]. The main types of data 
analysis used were the Chi-square test, t-test, Fisher’s exact test, Kaplan-Meier survival analysis, 
and odds ratio. The studies can be split into assessing the prevalence of AUDs among Russian TB 
patients, treatment outcomes, and interventions.  
 
5.2.1  Prevalence 
TB physicians in the Russian Federation believe alcoholism is a risk factor for TB [86]. 
Several studies confirmed high AUD rates among TB patients in the Russian Federation [53, 55, 
70, 85, 87, 88]. Researchers identified how many TB patients with current and previous AUDS 
using previous medical records and self-reporting. AUDIT scores were used to determine the use 
of alcohol in TB patients. The prevalence of AUD among TB patients in the Russian Federation 
ranges from 17.2% to 67.7%  [87, 88]. One study that compared AUD in male and female TB 
patients found that 28.3% of females and 70.6% of males had lifetime alcohol abuse or dependence 
[89]. Females with AUD in the study consumed on average 12 standard drinks a day, and males 
consumed about 16 standard drinks a day. The average AUDIT scores ranged from 11.5 to 18.3 in 
Russian TB patients [55, 82, 83, 89]. In these studies, over half the participants had an AUDIT 
score of eight or higher.  
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5.2.2  Treatment Outcome 
Alcohol is associated with a higher risk for poor treatment outcomes in the Russian 
Federation [88, 90]. TB patients with a previous history of AUD or a current diagnosis are at an 
increased risk for defaulting during treatment [91]. Alcohol consumption is associated with an 
increased risk for interruptions and adverse effects [91-93]. Russian TB patients were three to 
almost six times more likely to experience disruption during treatment if they have AUD [94]. In 
an older study, they found alcohol increased the risk of drug-resistant TB eight-fold [70]. Heavy 
alcohol consumption results in delayed surgery until they can decrease or stop their intake [82]. 
Alcohol impacts the treatment process and outcome for TB patients in the Russian Federation. 
Alcohol contributed to death in TB patients directly or indirectly [95]. Those who 
consumed alcohol during treatment have a higher mortality rate than those who do not [74, 95-97]. 
About 35.4 % of all male and 32% of all female TB deaths from 1980-2010 in the Russian 
Federation could be attributed to alcohol [97]. TB mortality increased when patients consumed 40 
grams or more of pure alcohol in one day during treatment [97]. One standard drink of alcohol 
contains about 14 grams of pure alcohol. Overall, alcohol negatively impacts the survival rate of 
TB patients in the Russian Federation.  
5.2.3  Interventions 
TB physicians do not receive sufficient training to diagnose and treat patients with 
substance abuse and addiction disorders [85]. The narcologists are specialists trained to treat 
patients for AUD in the Russian Federation. There may be a narcologist working at TB clinics, 
otherwise, patients must travel to a narcology center for treatment. In 2006 TB physicians, in the 
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city of Tomosk were trained to use AUDIT to screen TB patients for possible AUD [85]. 
Researchers found that more TB patients were screened for AUD and successfully referred to a 
specialist for treatment. The Integrated Management of Physician delivered Alcohol Care to 
Tuberculosis patients (IMPACT) is a randomized control trial in the Russian Federation that 
trained TB physicians to treat TB patients with AUD using behavioral and pharmacological 
interventions. They would provide a combination of oral naltrexone, brief behavioral compliance 
enhancement therapy (BBCET), or no treatment for AUD. Studies found that brief counseling 
interventions (BCI) effectively improved their treatment outcome in TB patients with AUD [81, 
83, 84]. Found TB patients with AUD treated with naltrexone, BBCET, and BCI in the 
contemplative stage had better outcomes than those in the pre-contemplative stage. The authors 
identified that most TB patients in the study were in the pre-contemplative stage of change. In 
Appendix B, the transtheoretical model of change describes the pre-contemplative stage as 





The literature review articles identified a wide prevalence of AUD among Russian TB 
patients. The prevalence of AUD varied by region across the Russian Federation and use of alcohol 
measurements. Compared to those using the AUDIT scores to measure alcohol use, there was a 
lower prevalence across studies that relied on current or previous clinician diagnosis of AUD in 
TB patients and patients self-reporting their alcohol use. Researchers were able to implement 
AUDIT in the Tomosk TB clinic successfully. However, they were not able to integrate behavioral 
therapy and medication intervention to improve treatment compliance. According to physicians, 
they were not accustomed to utilizing behavioral therapy treatment before. The physicians did not 
believe patients were comfortable with goal setting and discussing problems with alcohol. 
Limitations of several articles were no standardized alcohol use measurements. Self-reporting 
alcohol use can be affected by social desirability bias.  
Another growing concern in the Russian Federation is the HIV epidemic. In 2018, there 
were a total of 1 million cases of HIV, and this number has increased by about 10 to 15%  each 
year in the Russian Federation [98]. Risky behaviors include multiple sexual partners, lack of 
protection, and intravenous drug use. Patients with AUD and TB were 2.5-3 times more likely to 
have risky behaviors related to HIV [70]. Risky behaviors include multiple sexual partners, lack 
of protection, and intravenous drug use. 
The Russian Federation has been combating the high alcohol consumption rates by 
implementing new policies restricting alcohol production and sales. The country has seen a 
decrease in alcohol consumption and AUD diagnosis. However, they have done little to improve 
the treatment of citizens with AUD. In the Russian Federation, citizens dealing with alcohol use 
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problems are not encouraged to speak up about the issue [81]. Along with the stigmatizing 
narcology registry, Russian citizens are less likely to seek help for their unhealthy alcohol use. 
Another barrier faced by individuals with AUD is the lack of outpatient narcology centers in rural 
areas [99]. Since narcology centers are in cities, Russian citizens in rural areas can find it difficult 
to commute to a narcology center to receive treatment. Russian citizens should be encouraged to 
seek out treatment for AUDs. There should be various treatment options available for patients to 




Alcohol is a significant part of the culture in the Russian Federation. Since alcohol is related 
to several health-side effects and behavioral risks, the Russian Federation has successfully 
established policies that decreased alcohol consumption since the early 2000s. Patients consuming 
alcohol during treatment have a higher risk of treatment failure and progressing to MDR-TB. This 
makes it challenging to contain the drug-resistant epidemic in the Russian Federation. Although 
the IMPACT study did not yield significant results for improved treatment outcomes, it did 
highlight that many TB patients are in the pre-contemplative stage. Interventions can be tailored 
to help individuals in the pre-contemplative stage advance to the contemplation stage to be 
prepared to take action ultimately. 
There should be total anonymity when treating patients for any substance abuse disorder 
without concerns of the stigmatizing narcology registry. Narcology centers should have clinics 
located in rural areas to allow more patients to have ease of access to treatment. The Russian 
Federation should also offer more treatment options besides pharmacological interventions to 








Appendix Figure 1 Comparison of DSM-IV and DSM-5 Diagnostic Criteria 
Source: NIAA 
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Appendix Table 1 DSM-IV, DSM-5, ICD-10, and ICD-11 Alcohol Diagnosis Definitions 




Appendix B Transtheoretical Table 
 
Appendix Table 2 Transtheoretical Stages of Change 
Source: Nidecker et al., 2008 [100] 
Stage Definition 
Pre-contemplation Individual is unaware their behavior is 
problematic. They have no desire to change. 
Contemplation Individual recognizes unhealthy behavior. 
Preparation Individual is ready to take action to change 
behavior. 
Action Individual is changing their behavior or 
replacing it with another. 
Maintenance Individual has maintained modified behavior 
for more than 6 months.  
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